Subcutaneous Administration

FDA Approves At‑Home Weekly Subcutaneous Starter Dose for Leqembi

Relying on pharmacokinetic bioequivalence rather than new outcome trials, the agency cleared at‑home initiation to expand access and reduce infusion demand.